Endocannabinoid System Dysfunction Validation in Parkinson's Disease

Experiment Overview

Experiment ID: ECS-PD-001 Hypothesis: Endocannabinoid system dysfunction drives dopaminergic neurodegeneration through impaired motor circuit regulation, neuroimmune dysregulation, and protein homeostasis disruption.

Primary Objective: Validate ECS dysfunction as a disease mechanism in PD and assess CB1/CB2 modulation as a disease-modifying therapeutic strategy.

Study Design: Multi-phase (preclinical -> Phase II clinical)

Phase 1: Preclinical Validation (12 months)

1.1 In Vitro Studies

Experiment Overview

Experiment ID: ECS-PD-001 Hypothesis: Endocannabinoid system dysfunction drives dopaminergic neurodegeneration through impaired motor circuit regulation, neuroimmune dysregulation, and protein homeostasis disruption.

Primary Objective: Validate ECS dysfunction as a disease mechanism in PD and assess CB1/CB2 modulation as a disease-modifying therapeutic strategy.

Study Design: Multi-phase (preclinical -> Phase II clinical)

Phase 1: Preclinical Validation (12 months)

1.1 In Vitro Studies

A. Human iPSC-Derived Dopaminergic Neurons

• Model: iPSCs from PD patients with LRRK2 G2019S mutation vs. healthy controls
• Endpoint: CB1/CB2 receptor expression (qPCR, Western blot), endocannabinoid levels (LC-MS/MS), viability after MPTP/rotenone exposure
• Hypothesis: PD neurons will show reduced CB1 expression and lower baseline anandamide/2-AG

• Model: Primary microglia + dopaminergic neurons (either alone or co-cultured)
• Intervention: CB2 agonist (JWH-133, 100nM) vs. CB2 antagonist (AM-630, 200nM)
• Endpoints: IL-1β, TNF-α secretion (ELISA), alpha-synuclein aggregation (Thioflavin-S), neuronal survival (MTT)
• Hypothesis: CB2 activation will reduce neuroinflammation and alpha-synuclein aggregation in co-culture

1.2 In Vivo Studies

A. Alpha-Synuclein Preformed Fibril (PFF) Mouse Model

• Animals: C57BL/6 mice (male, 10-12 weeks)
• Groups (n=20 per group):

• Duration: 12 weeks post-PFF injection
• Endpoints:
• Behavioral: cylinder test, stepping test, rotarod
• Biochemical: tyrosine hydroxylase (TH) in SNc (IHC), alpha-synuclein pSer129 (IHC, WB)
• Molecular: CB1/CB2 expression, cytokine profiling (multiplex), endocannabinoid levels (LC-MS/MS)
• Imaging: [18F]FDG PET for metabolic assessment

• Cross: CNR1-/- mice × Thy1-αSyn mice
• Endpoints: Motor behavior, survival, neuropathology
• Hypothesis: Double mutants will show accelerated neurodegeneration

1.3 Mechanism Elucidation

• RNA-seq of SNc from treated vs. control mice (pathway enrichment: neuroinflammation, autophagy, mitochondrial function)
• Proteomics of postsynaptic density fractions
• Metabolomics of brain tissue and CSF

Phase 2: Clinical Biomarker Study (6 months)

2.1 Cross-Sectional Biomarker Assessment

Cohort: 120 participants

| Group | N | Criteria |
|-------|---|----------|
| PD patients (early, H&Y 1-2) | 60 | Diagnosis <2 years, not on cannabis/CB medications |
| PD patients (advanced, H&Y 3-4) | 30 | Disease duration >5 years |
| Healthy controls | 30 | Age-matched, no neurological disease |

Endpoints:

• Anandamide (AEA)
• 2-arachidonoylglycerol (2-AG)
• N-oleoylethanolamine (OEA)
• N-palmitoylethanolamine (PEA)

• IL-1β, IL-6, TNF-α (multiplex)
• Neurofilament light chain (NfL) as neurodegeneration marker

• MDS-UPDRS Parts I-III
• Non-Motor Symptoms Scale (NMSS)
• Montreal Cognitive Assessment (MoCA)
• REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ)

• Multivariate analysis to identify endocannabinoid signatures discriminating PD vs. controls
• Correlation of endocannabinoid levels with disease severity (MDS-UPDRS), duration, and NfL

2.2 Longitudinal Biomarker (Optional Extension)

• Cohort: 40 early PD patients
• Duration: 12 months
• Endpoints: Repeat CSF sampling at 6 and 12 months
• Hypothesis: Declining AEA levels will correlate with disease progression

Phase 3: Phase II Clinical Trial (18 months)

Trial Design

Title: ECS-PD-001: CB2 Agonist (JWH-133 analog) as Disease-Modifying Therapy in Early Parkinson's Disease

Design: Randomized, double-blind, placebo-controlled, parallel-group

Population:

• N = 120 (estimated based on power calculation: 80% power to detect 3-point MDS-UPDRS difference, α=0.05, 20% dropout)
• Inclusion: H&Y stage 1-2, disease duration <3 years, not on dopaminergic therapy or requiring ≤1/day levodopa dose

| Arm | Intervention | Dose |
|-----|--------------|------|
| 1 | Placebo | Vehicle (saline) |
| 2 | CB2 agonist (GT-2017) | 5mg/day oral |
| 3 | CB2 agonist (GT-2017) | 10mg/day oral |

Endpoints

Primary (12 months):

• Change in MDS-UPDRS Part III (motor) score from baseline
• Time to initiation of dopaminergic therapy (rescue)

• Change in MDS-UPDRS Parts I, II, IV
• Change in NMSS total score
• Change in MoCA
• CSF biomarkers subset (n=40): AEA, 2-AG, IL-1β, NfL
• DaTscan progression (change in striatal binding ratio)

• Subgroup analysis by CNR1/FAAH genotype
• Machine learning on wearable sensor data (gait, tremor)

Safety Monitoring

• Adverse event tracking (expected: mild GI symptoms, dizziness)
• Psychiatric assessment (SCID-P, monitoring for depression/anxiety)
• Liver function tests (monitoring for off-target effects)

Success Criteria

Preclinical Phase

Clinical Phase

Resource Requirements

| Item | Estimated Cost |
|------|----------------|
| Preclinical studies | $450,000 |
| Biomarker study | $200,000 |
| Phase II trial | $2,500,000 |
| Total | $3,150,000 |

Timeline

| Phase | Duration | Key Milestones |
|-------|----------|----------------|
| Phase 1 (Preclinical) | Month 1-12 | In vitro completion, in vivo recruitment, interim analysis |
| Phase 2 (Biomarker) | Month 10-16 | Cohort recruitment, assay validation |
| Phase 3 (Clinical) | Month 14-32 | IND submission (Month 12), trial initiation (Month 14) |
| Analysis & reporting | Month 30-36 | Final analysis, publication |

Risk Mitigation

| Risk | Mitigation |
|------|------------|
| CB2 agonist not reaching brain | Use brain-penetrant analogs; verify CSF exposure |
| Insufficient enrollment | Multi-site trial (5-7 sites) |
| Off-target effects | Thorough preclinical toxicology; dose-finding study |
| Psychiatric adverse events | Careful exclusion criteria; close monitoring |

References